What were the key takeaways from Vivos's earnings call?

What is Vivos's gross profit margin?

What does Vivos do and what are its main business segments?

What is the market's earnings forecast for Vivos next quarter?

What were the key takeaways from Vivos’s earnings call?

What guidance did Vivos's management provide for the next earnings period?

What is Vivos's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Vivos year over year?

- **Strategic Pivot Success**: SCN acquisition generated $500k revenue in 20 days, with 1.5 SO teams processing 250 patients/month.
- **Financial Transition**: Q2 operating loss of $4.9M driven by $1.8M one-time costs, but $11.5M financing provides liquidity.
- **Growth Catalysts**: Targeting 8 SO teams by 2026, with Michigan expansion under new collaboration model.
- **Cash Flow Target**: Aiming for Q4 2025 cash flow breakeven as SO teams scale.

**【CFO Financial Overview】**
- Q2 2025 revenue decreased 6% to $3.8 million due to strategic pivot away from legacy VIP enrollment model, offset by $500,000 sleep testing revenue from SCN acquisition.
- Operating loss widened to $4.9 million due to $1.8 million in one-time acquisition costs (legal fees, salaries, infrastructure) and $600,000 product discounts.
- Cash flow improved with $11.5 million in financing from Seneca Partners, but cash reserves remain at $4.4 million.

**【CEO Strategic Pivot】**
- Acquired The Sleep Center of Nevada (SCN) in June 2025, generating $500,000 revenue in 20 days post-close.
- Deployed 1.5 Sleep Optimization (SO) teams capable of processing 250 patients/month, targeting 8 teams by 2026 with $500k+ monthly net collections per team.
- Patient demand exceeds capacity, with <40% of tested patients currently treated.
- Expanded into Michigan with MISleep LLC under new collaboration model, planning 1 SO team deployment by Q4.

**【Q&A Highlights】**
- **Revenue Growth**: Q3/Q4 revenue will track SO team deployment, with product sales growth driven by SCN referrals.
- **Operating Expenses**: $700k-$800k of Q2 OpEx were one-time acquisition costs; recurring expenses include $500k in salaries and $300k in infrastructure.
- **Recruitment**: SO teams recruited and trained in ~6-8 weeks, with strong candidate pipeline.
- **Debt Strategy**: Seeking to refinance high-cost debt as model matures; targeting cash flow breakeven by Q4 2025.
- **Market Expansion**: Multiple acquisition prospects in pipeline, including one under exclusive LOI.

Vivos Therapeutics (VVOS)-19 Aug 25-2025 Q2 Earnings call transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

VVOS

VVOS fundamentals

You can ask Aime